Changes in serum immunoglobulin G glycosylation patterns for antiphospholipid syndrome patients with lectin microarray
Scandinavian Journal of Immunology · 2024
DOI: 10.1111/sji.13366 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scandinavian Journal of Immunology, 2024. Verfasst von Yifei Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Hauptthemen laut MEDLINE: Antiphospholipid Syndrome, Immunoglobulin G. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The National Key Research and Development Program of China, National High-Level Hospital Clinical Research Funding, National Key Research and Development Program of China.
Abstract (Originalsprache)
Antiphospholipid syndrome is a rare autoimmune disease characterized by persistent antiphospholipid antibodies. Immunoglobulin G plays a vital role in disease progression, with its structure and function affected by glycosylation. We aimed to investigate the changes in the serum immunoglobulin G glycosylation pattern in antiphospholipid syndrome patients. We applied lectin microarray on samples from 178 antiphospholipid syndrome patients, 135 disease controls (including Takayasu arteritis, rheumatoid arthritis and cardiovascular disease) and 100 healthy controls. Lectin blots were performed for validation of significant differences. Here, we show an increased immunoglobulin G‐binding level of soybean agglutinin ( p = 0.047, preferring N‐acetylgalactosamine) in antiphospholipid syndrome patients compared with healthy and disease controls. Additionally, the immunoglobulin G from antiphospholipid syndrome patients diagnosed with pregnancy events had lower levels of fucosylation ( p = 0.001, recognized by Lotus tetragonolobus ) and sialylation ( p = 0.030, recognized by Sambucus nigra I) than those with simple thrombotic events. These results suggest the unique serum immunoglobulin G glycosylation profile of antiphospholipid syndrome patients, which may inform future studies to design biomarkers for more accurate diagnosis of antiphospholipid syndrome and even for the prediction of clinical symptoms in patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China.
- Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.
- Department of Clinical Laboratory, Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
ORCID-Profile: Yifei Wang
Förderung
- The National Key Research and Development Program of China
- National High-Level Hospital Clinical Research Funding
- National Key Research and Development Program of China
Zitieren
APA
Wang, Y., Li, S., Meng, J., Yu, R., Wang, Q., Tian, X., Li, M., Zeng, X., Zhao, J., & Hu, C. (2024). Changes in serum immunoglobulin G glycosylation patterns for antiphospholipid syndrome patients with lectin microarray. Scandinavian Journal of Immunology. https://doi.org/10.1111/sji.13366
Vancouver
Wang Y, Li S, Meng J, Yu R, Wang Q, Tian X, et al. Changes in serum immunoglobulin G glycosylation patterns for antiphospholipid syndrome patients with lectin microarray. Scandinavian Journal of Immunology. 2024. doi:10.1111/sji.13366
BibTeX
@article{Wang2024,
author = {Wang, Yifei and Li, Siting and Meng, Jingjing and Yu, Rui and Wang, Qian and Tian, Xinping and Li, Mengtao and Zeng, Xiaofeng and Zhao, Jiulang and Hu, Chaojun},
title = {Changes in serum immunoglobulin G glycosylation patterns for antiphospholipid syndrome patients with lectin microarray},
journal = {Scandinavian Journal of Immunology},
year = {2024},
doi = {10.1111/sji.13366}
}
EUVIMED